

# Long-Acting Injectable Drugs

Technology, Therapeutics, Markets, &  
Forecasts

Report Brochure

Greystone  
Research Associates




Greystone Research Associates is pleased to announce the publication of a new market study. **Long-Acting Injectable Drugs: Technology, Therapeutics, Markets and Forecasts** is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector.

The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for injectable drug products engineered for controlled release. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

### Engineered Injectables that Address Chronic Conditions

Chronic conditions require drug administration over long periods of time, placing a greater emphasis on self-administration. With the shift away from caregiver interaction, drug safety and compliance/adherence become prominent concerns. These concerns, which are not new, are becoming magnified as the number of powerful new drugs reaching the market increases. For healthcare managers and public health officials, one way to address these issues is less frequent dosing. Using formulation technologies designed to modulate the effect of therapeutic substances, drug developers are creating formulations that exhibit extended-release profiles. These chemistries include polymers such as polyethylene glycol-complexed (PEGylated), which are used to product encapsulated and coated versions of new APIs. The goal is to address the requirement for patient-dependent, and therefore compliance-sensitive, drug treatment protocols such as multiple dosing through controlled release formulations that provide the desired therapeutic effect with dosing of once-a-day or less.

### Report Value Matrix



## **Executive Summary**

Long-Acting Injectable Drugs  
Executive Summary  
Injectable Drug Market  
Dynamics  
The Trend toward Self-Administration

## **Injectable Drug Formulation Technology**

Innovation in Injectable  
Device Designs  
Therapeutic Demand Drivers

## **Market Factors**

Patient Compliance  
Ease of Use  
Healthcare Regulations  
Managed Care Initiatives  
Competitive Landscape  
Risk Factors

## **Formulation Technologies**

Biodegradable Polymers  
PEG  
PLA/PLGA  
Polyether ester  
Long-Acting Injectable  
Formulation Technologies  
BEPO (MedinCell)  
ChroniJect (Oakwood  
Laboratories/PharmaSophia)

CriticalMix (Critical  
Pharmaceuticals)  
Depofoam (Pacira)  
FluidCrystal (Camarus)  
LinkeRx (Alkermes)  
Medisorb (Alkermes)  
Medusa (Recipharm/Avadel)  
Nanocrystals (Alkermes)  
Optisomes (Talon/Spectrum)  
PolyActive (Octopus)  
Q-Sphera (Midatech Pharma)  
SABER/SAIB (DURECT)  
SynBiosys (Innoco)  
TransCon (Ascendis)

## **Physical Process Control**

### **Methods**

Supercritical Fluid  
SCF for Nanoparticle  
Formulations  
Formulplex (Supercritical  
Solutions)  
Ferro SCF extraction of  
emulsions (SFEE)

## **Long-Acting Injectables – Development Factors**

Formulation Factors  
Stability  
Administration Factors

## **Long-Acting Product Analysis**

Aripiprazole  
Aripiprazole lauroxil  
Bupivacaine  
Buprenorphine  
Cytarabine  
Cytarabine & Daunorubicin  
Doxorubicin  
Estradiol  
Exenatide  
Fluphenazine decanoate  
Goserelin acetate  
Granisetron  
Interferon (1)  
Interferon (2)  
Interferon (3)  
Interferon (4)  
Irinotecan  
Lanreotide acetate  
Leuprolide  
Leuprolide Depot  
Medroxyprogesterone  
Naltrexone  
Octreotide acetate  
Olanzapine Pamoate  
Paliperidone palmitate  
Pasireotide  
Pegvaliase-pqpz  
Risperidone  
Testosterone  
Triptorelin (1)  
Triptorelin (2)  
Triamcinolone acetonide

Vincristine sulfate  
Glycemic Control  
AB101 (Rezolute)  
Hormone Deficiency  
human Growth Hormone/  
Ascendis Pharma  
Addiction  
CAM2038 (Camurus)  
Pain Management  
Posidur/Durect  
Cardiology  
Treprostinil/Ascendis Pharma  
Neurology  
Relday/Risperidone  
(DURECT/Zogenix)  
Oncology  
CAM2032 (Camurus)

## **Therapeutic Sector Analysis**

Addiction  
Glycemic Control  
Infectious Disease  
Hepatitis  
Neurology  
Schizophrenia  
Bipolar Disorder  
Oncology  
Pain Management  
Reproductive Health  
Fertility  
Endometriosis

## **Company Profiles**

## What You Will Learn

- What are the marketed long-acting injectable drug products, what Long-Acting formulation technologies are used, and who markets them?
- What are the major factors driving long-acting injectable drug demand?
- What long-acting injectable drug candidates are in late-stage clinical development and what is their potential impact?
- How important are drug developer-formulation technologist relationships in the long-acting market segment, and what are the key alliances in the industry?
- What are the essential formulation factors, delivery device selection issues, related technology factors and market development issues for long-acting injectable drug products?
- In what therapeutic market segments do long-acting injectables compete? What is their market share today? What will it be in 2028? What is their expected growth rate?
- What are the significant economic, technology, and regulatory factors affecting the market for long-acting injectables?

## Report Format and Availability

This report is available electronic format. A site license for a single physical location and a global license are also available. Custom licensing options to address specific company user requirements are available by calling client services at 603-440-5710, or by emailing [clientservices@greystoneassociates.org](mailto:clientservices@greystoneassociates.org).

## Methodology

Research methodology is based on primary research in the form of in-depth interviews with key market participants, technology developers, distributors, industry experts, and market influencers, a list that includes regulatory officials, industry trade groups, and materials standards organizations.

Primary data is evaluated and normalized against secondary sources including trade journal articles, technical literature, industry publications, company data sheets and published information, and statistical data from government agencies and trade associations.

Forecasts and projections of market demand and future market activity are derived using standard modeling and statistical techniques.

## About Greystone Associates

Greystone Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis.

Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.

## Ordering Information

Orders may be placed via postal mail, e-mail or fax. Orders not accompanied by a purchase order must contain a telephone number for verification, and clearly indicate the physical shipping address and billing address.

### Payment

We accept the following forms of payment:

**Company Check:** Please make checks payable to 'Greystone Associates'

**Credit Cards:** We accept MasterCard, Visa and American Express

**Wire Transfers:** See 'Wire Transfers' below for more information

### Orders Outside the U.S.

Orders must be prepaid via credit card, company check in US funds and drawn on a US bank, or wire transfer.

Email to  
[research@greystoneassociates.org](mailto:research@greystoneassociates.org)

**Wire Transfers:** TD Banknorth  
300 Franklin Street  
Manchester, NH 03103  
(Call for Account Information)

**Mailing Address:** Greystone Research Associates  
Client Services  
P.O. Box 1362  
Amherst, NH 03031

## Long-Acting Injectable Drugs

### Technology, Therapeutics, Markets & Forecasts

| Select                            | Format | License             | Price (U.S. Funds) | Total |
|-----------------------------------|--------|---------------------|--------------------|-------|
| <input type="checkbox"/>          | PDF    | Single User License | \$3,850.00         |       |
| <input type="checkbox"/>          | PDF    | Site License        | \$5,500.00         |       |
| <input type="checkbox"/>          | PDF    | Global License      | \$7,500.00         |       |
| <b>Total Payment (U.S. funds)</b> |        |                     |                    |       |

Method of Payment:  Company Check        Wire Transfer (International)

Card Number: \_\_\_\_\_ Name on Card \_\_\_\_\_

Expiration Date: \_\_\_\_\_ Card CVV \_\_\_\_\_ Signature \_\_\_\_\_

| Billing Information  | Shipping Information  |
|----------------------|---|
| Name:                | <input type="checkbox"/> Click here if same as Billing Information<br>Name: |
| Title:               | Title:  |
| Company:             | Company:  |
| Street Address:      | Street Address:   |
| City,State/Province: | City,State/Province:  |
| Country/Postal Code: | Country/Postal Code:  |
| Phone:               | Phone:  |
| Fax:                 | Fax:  |
| Email:               | Email:  |